EIR Biopharma, Inc. IPO - Investor's Guide

Considering an investment in EIR Biopharma's upcoming IPO? The biopharma sector can be complex, so let's break down the essential details in clear, accessible language to help you make an informed decision.

1. What does EIR Biopharma do?

EIR Biopharma is a clinical-stage biotechnology company developing transformative gene therapies for severe, rare genetic diseases. Our mission is to "reprogram" faulty cells at a fundamental level, aiming for one-time, potentially curative treatments rather than just managing symptoms.

We specifically focus on adeno-associated virus (AAV)-mediated gene therapies, which use a modified virus to deliver therapeutic genes. Our lead product candidate, EIR-001, is in Phase 1/2 clinical trials for Huntington's Disease, a devastating neurodegenerative disorder. EIR-001 aims to deliver a functional copy of the huntingtin gene directly to brain cells. We also have a robust preclinical pipeline, including EIR-002 for Cystic Fibrosis and EIR-003 for a rare form of Muscular Dystrophy. Both utilize our proprietary AAV capsids for more effective gene delivery.

Our scientific foundation is strong, built on exclusive licensing agreements with leading institutions like the University of Miami and Cornell University. These agreements give us access to foundational AAV vector technology and specific disease-targeting intellectual property.

2. How do they make money and are they growing?

As a clinical-stage biotech company, EIR Biopharma is currently in the "spending money" phase, heavily investing in research and development to advance our pipeline. We do not yet have any products on the market generating significant sales.

Our funding to date has primarily come from:

• Venture Capital & Private Funding: We successfully raised $120 million in private capital. This includes $75 million from Series A Preferred Stock and $45 million from convertible notes payable and warrants issued to institutional and individual investors. These convertible notes and warrants could convert into common stock, potentially diluting existing shareholders.
• Strategic Partnerships & Grants: We received $5 million in non-dilutive grants from disease-specific foundations to support our preclinical research.

For the fiscal year ended December 31, 2023, EIR Biopharma reported a net loss of $48.5 million and an accumulated deficit of $135 million. Our cash and cash equivalents were $32 million as of March 31, 2024. For a company at our stage, "growth" is measured by the successful progression of our drug candidates through clinical trials and regulatory milestones, which are critical for future revenue generation.

3. What will they do with the money from this IPO?

We anticipate raising approximately $150 million (net of underwriting discounts and commissions) from this IPO. These funds are crucial to fuel our scientific engine and advance our promising drug candidates:

• Approximately 50% ($75 million) will fund the ongoing Phase 1/2 clinical trial for EIR-001 in Huntington's Disease. This includes patient enrollment, data collection, and analysis, with an expected readout in late 2026.
• Approximately 30% ($45 million) will advance our preclinical pipeline, including IND-enabling studies for EIR-002 (Cystic Fibrosis) and EIR-003 (Muscular Dystrophy). We plan to file Investigational New Drug (IND) applications for both by mid-2026. This allocation also covers ongoing research to discover new AAV-mediated gene therapy candidates.
• Approximately 10% ($15 million) will go towards manufacturing and process development. This includes establishing partnerships with contract manufacturing organizations (CMOs) to scale up production of our AAV vectors.
• The remaining 10% ($15 million) will cover general corporate purposes, including working capital, hiring key scientific and operational talent, license fees, patent costs to protect our intellectual property, and general administrative expenses.

4. What are the main risks I should worry about?

Investing in a clinical-stage biopharma company like EIR carries significant risks:

• Clinical Trial Failure: The biggest risk is that our lead candidate, EIR-001, or any future candidates, may fail to demonstrate safety or efficacy in human trials. Gene therapies, especially for neurological disorders like Huntington's, present unique challenges, and many promising drugs fail in later stages.
• Regulatory Approval: Even if trials are successful, obtaining regulatory approval from agencies like the FDA is a lengthy, complex, and uncertain process. There's no guarantee of approval, and delays can be costly.
• Competition: The gene therapy space is highly competitive. Other companies, including larger pharmaceutical firms and smaller biotechs, are developing treatments for Huntington's Disease, Cystic Fibrosis, and Muscular Dystrophy. A competitor could develop a superior or earlier-to-market therapy.
• Funding Needs & Dilution: Developing gene therapies is incredibly expensive. We will likely require substantial additional funding beyond this IPO to complete clinical development and commercialize our products. Future fundraising efforts could dilute your ownership percentage. The $45 million in convertible notes and warrants issued previously could also convert into common stock, further increasing the share count.
• Intellectual Property: Our success hinges on our ability to protect our proprietary AAV technology and gene therapy constructs. Our key patents for EIR-001 are expected to expire between 2038 and 2042. Challenges to our patents or the expiration of key intellectual property could significantly impact our competitive position.
• Manufacturing Complexity: Producing high-quality, clinical-grade AAV vectors is a complex and costly process. Any manufacturing issues could delay development or commercialization.

5. How do they compare to competitors?

EIR Biopharma is a focused, clinical-stage gene therapy company, distinct from diversified pharmaceutical giants like Pfizer or Johnson & Johnson. Our direct competitors are other innovative biotech companies specializing in gene therapy for rare diseases. These include companies like Voyager Therapeutics (also working on Huntington's Disease gene therapy), Sarepta Therapeutics (focused on muscular dystrophies), and Vertex Pharmaceuticals (with a strong presence in Cystic Fibrosis). We aim to differentiate ourselves through our proprietary AAV capsid technology, designed for more precise targeting and fewer immune reactions.

6. Who's running the company?

Our leadership team combines deep scientific expertise with extensive industry experience:

• Dr. Anya Sharma, CEO: A seasoned biotech executive with over 20 years of experience, including leading the successful development and commercialization of two rare disease therapies at her previous company, Genoscience Inc.
• Dr. Ben Carter, Chief Scientific Officer (CSO): A pioneer in AAV gene therapy, Dr. Carter is a co-founder of EIR Biopharma. He was previously a tenured professor at the University of Miami, where he conducted groundbreaking research on neurodegenerative gene therapies.

An experienced board of directors supports the team, which also works with specialized consultants (e.g., for regulatory affairs and clinical trial management). We also have a 2023 Equity Incentive Plan reserving 15% of our common stock for future grants, designed to attract and retain top talent by aligning employee interests with shareholder value.

7. Where will it trade and under what symbol?

Upon completion of the IPO, EIR Biopharma's common stock will list on the NASDAQ Global Market under the ticker symbol "EIRB".

8. How many shares and what price range?

EIR Biopharma plans to offer 10,000,000 shares of common stock to the public. The estimated initial price range for these shares is between $14.00 and $16.00 per share. The final offering price will be determined on the evening before the stock begins trading.